PRESS RELEASE published on 08/19/2025 at 06:59, 8 months 21 days ago Medartis delivers 15.3% organic sales growth in H1 and lifts sales guidance for the full-year
BRIEF published on 07/30/2025 at 10:04, 9 months 10 days ago Medartis présentera ses résultats semestriels 2025 en webcast Résultats Semestriels Webcast Dispositifs Médicaux Medartis Séance De Questions-réponses
BRIEF published on 07/30/2025 at 10:04, 9 months 10 days ago Medartis to Present 2025 Half-Year Results in Webcast Medical Devices Webcast Half-year Results Q&A Session Medartis
PRESS RELEASE published on 07/30/2025 at 09:59, 9 months 10 days ago Medartis 2025 half-year results webcast Medartis Holding AG to present 2025 half-year results via webcast on August 19, 2025. CEO Matthias Schupp and CFO Dirk Kirsten to speak. Event details and registration link provided Webcast Medartis Holding AG Dirk Kirsten Matthias Schupp 2025 Half-Year Results
BRIEF published on 07/17/2025 at 07:04, 9 months 23 days ago Medartis finalise l'acquisition complète de KeriMedical Approbation De La FDA KeriMedical Acquisition De Medartis Remplacement Articulaire Prothèse TOUCH
BRIEF published on 07/17/2025 at 07:04, 9 months 23 days ago Medartis Finalizes Full Acquisition of KeriMedical FDA Approval Medartis Acquisition KeriMedical Joint Replacement TOUCH Prosthesis
PRESS RELEASE published on 07/17/2025 at 06:59, 9 months 23 days ago Medartis acquires remaining 53% stake in KeriMedical Medartis acquires remaining 53% stake in KeriMedical, strengthening position in joint replacement & expanding surgeon network. Acquisition valued at CHF 99 million in cash with FDA-approved flagship product TOUCH Acquisition FDA Approval Medartis KeriMedical Joint Replacement
PRESS RELEASE published on 03/18/2025 at 06:59, 1 year 1 month ago Medartis delivers 12% core sales growth in 2024 and improves its core EBITDA margin from 17% to 19%
PRESS RELEASE published on 08/20/2024 at 07:05, 1 year 8 months ago Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US (21%) and EMEA (18%) –improvement of EBITDA* margin to 17%
BRIEF published on 07/09/2024 at 07:04, 1 year 10 months ago Matthias Schupp nommé PDG de Medartis Technologie Médicale Nomination Du PDG Medartis Matthias Schupp
Published on 05/09/2026 at 01:30, 11 hours 49 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 13 hours 19 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 16 hours 40 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 18 hours 6 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 18 hours 16 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 18 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 18 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 18 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 18 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 18 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
